^
    Back
    Association details:
    Biomarker:HER-2 overexpression
    Cancer:Breast Cancer
    Drug:Trazimera (trastuzumab-qyyp) (HER2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    FDA
    Excerpt:
    TRAZIMERA is a HER2/neu receptor antagonist indicated for: The treatment of HER2-overexpressing breast cancer....as part of a treatment regimen consisting of doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel….as part of a treatment regimen with docetaxel and carboplatin….In combination with paclitaxel for first-line treatment of HER2-overexpressing metastatic breast cancer…
    Secondary therapy:
    paclitaxel; paclitaxel + doxorubicin hydrochloride + cyclophosphamide; docetaxel + doxorubicin hydrochloride + cyclophosphamide; carboplatin + docetaxel
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    A Study Of PF-05280014 Or Trastuzumab Plus Taxotere® And Carboplatin In HER2 Positive Breast Cancer In The Neoadjuvant Setting (REFLECTIONS B327-04)

    Excerpt:
    ...- Histologically confirmed HER2 overexpressing invasive breast cancer....
    Trial ID:
    REFLECTIONS B327-04
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    A Study Of PF-05280014 [Trastuzumab-Pfizer] Or Herceptin® [Trastuzumab-EU] Plus Paclitaxel In HER2 Positive First Line Metastatic Breast Cancer Treatment (REFLECTIONS B327-02)

    Excerpt:
    ...- Documentation of HER2 gene amplification or overexpression....
    Trial ID:
    REFLECTIONS B327-02